Logo

Richard Marsh, Benjamin Jackson

Dec 17, 2018

Richard Marsh, executive VP of Myriad Genetics, as well as its general counsel and secretary, will retire from the company effective July 1, 2019.  After serving as Myriad's general counsel for more than 16 years, Marsh has acceped the job of mission president for the Church of Jesus Christ of Latter-day Saints for the next three years.

Benjamin Jackson, currently Myriad's VP, assistant general counsel, and assistant secretary, will succeed Marsh. Jackson has been with the company since 2006 and has held positions dealing with commercial operations and intellectual property issues.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.